CRDF
Cardiff Oncology Inc
1.30$
-2.3%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -5,643.3% | -4,576.3% | -3,775.6% | -5,662.6% | -6,337.0% | -6,799.3% | -11,737.6% | -6,882.6% | -9,028.3% | -2,455.6% | -29,970.7% | -11,312.5% | -8,042.1% | |
| 75.9% | 66.0% | 49.8% | 64.4% | 61.2% | 63.6% | 209.2% | 189.3% | 411.7% | 91.8% | 539.0% | -45.2% | 175.4% | |
| 677.3% | 582.7% | 548.3% | 723.3% | 759.4% | 797.4% | 1,252.3% | 1,390.9% | 1,153.3% | 518.9% | 4,048.8% | 884.6% | 1,028.5% | |
| 725.5% | 891.7% | 585.9% | 853.4% | 122.4% | 250.3% | -748.6% | 3,309.1% | -1,001.7% | -31.7% | -4,222.0% | -3,472.1% | -1,303.3% | |
| 223.4% | 5.1% | 39.0% | 0.0% | 0.0% | 0.0% | 0.0% | 21.5% | 15.0% | 0.0% | 0.0% | 42.3% | 12.2% | |
| 2,709.9% | 8,692.9% | 2,261.5% | 8,598.2% | -5,717.6% | 2,987.4% | -13,379.8% | -4,118.2% | 8,466.7% | 4,423.5% | 7,943.9% | 11,797.1% | 7,172.2% | |
| 4.3% | 7.7% | – | 3.7% | 3.6% | – | – | – | – | – | – | – | – | |
| -4.3% | 7.7% | 52.2% | 1,262.6% | 4,501.2% | 29,263.6% | 2.8% | 0.0% | 20.8% | 1,050.6% | 256.1% | 143.3% | 557.5% | |
| -2,933.3% | 4,116.7% | -1,462.0% | 4,198.2% | -7,553.3% | 25,451.7% | -25,114.7% | -11,000.8% | -540.8% | 3,018.5% | -21,770.7% | 627.9% | -312.4% | |
| -5,866.7% | -4,581.4% | -3,814.6% | -5,662.6% | -6,337.0% | -6,799.3% | -11,737.6% | -6,904.1% | -9,043.3% | -2,455.6% | -29,970.7% | -11,354.8% | -8,054.3% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.